key: cord-0986621-dc8x2v49
authors: Liu, Tianxiao; Luo, Songyuan; Libby, Peter; Shi, Guo-Ping
title: Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients
date: 2020-05-26
journal: Pharmacol Ther
DOI: 10.1016/j.pharmthera.2020.107587
sha: b50534c64cca221969fcaa7e3c2c2af403247e5f
doc_id: 986621
cord_uid: dc8x2v49

The widespread coronavirus SARS-CoV-2 has already infected over 4 million people worldwide, with a death toll over 280,000. Current treatment of COVID-19 patients relies mainly on antiviral drugs lopinavir/ritonavir, arbidol, and remdesivir, the anti-malarial drugs hydroxychloroquine and chloroquine, and traditional Chinese medicine. There are over 2118 on-going clinical trials underway, but to date none of these drugs have consistently proven effective. Cathepsin L (CatL) is an endosomal cysteine protease. It mediates the cleavage of the S1 subunit of the coronavirus surface spike glycoprotein. This cleavage is necessary for coronavirus entry into human host cells, virus and host cell endosome membrane fusion, and viral RNA release for next round of replication. Here we summarize data regarding seven CatL-selective inhibitors that block coronavirus entry into cultured host cells and provide a mechanism to block SARS-CoV-2 infection in humans. Given the rapid growth of the SARS-CoV-2-positive population worldwide, ready-to-use CatL inhibitors should be explored as a treatment option. We identify ten US FDA-approved drugs that have CatL inhibitory activity. We provide evidence that supports the combined use of serine protease and CatL inhibitors as a possibly safer and more effective therapy than other available therapeutics to block coronavirus host cell entry and intracellular replication, without compromising the immune system.

were laboratory-confirmed positive. These patients are asymptomatic carriers who make the transmission extremely difficult to monitor and control (Rothe et al., 2020) . Some patients develop dyspnea, multifocal pneumonitis that can cause a rapid decrease of blood oxygen saturation, and systemic cytokine storm, multisystem organ failure, and death .

Effective treatment of COVID-19 patients presents an urgent unmet need. While the world awaits the development of a protective vaccine for SARS-CoV-2, which infection morbidity and associated death toll is still on the rise, the discovery of clinically effective SARS-CoV-2-specific drugs has been the focus of governments, research institutions, drug companies, and hospitals worldwide. We hereby call attention to a novel mechanism of cysteinyl cathepsin L (CatL) activity in coronavirus surface spike protein proteolysis and propose a promising possibility of a protease inhibitor cocktail therapy to target host cell surface transmembrane serine protease 2 (TMPRSS2) and CatL on cell surfaces and inside the endosomes.

Since the outbreak of COVID-19 in China and then worldwide, the drug treatments offered to COVID-19 patients have shown inconsistent outcomes. Most drugs were administered based on the anti-coronavirus effects demonstrated in previous in vitro and patient studies. Figure 1 summarizes current registered COVID-19-associated trials through May 5, 2020 from various clinical trial registry sites. There are 2,118 trials in total and the majority of which are registered at ClinicalTrials.gov from the United States National Library of Medicine at the National Institutes of Health (n=1,076) and from the Chinese Clinical Trial Registry (ChiCTR) database (n=653) (Figure 1a ). Of these 2,118 trials, 1,273 were intervention studies to test the efficacy of medications with proper placebo or standard treatment controls. There are 756 observational trials in which researchers do not intervene but monitor participant disease progress for the purpose of information collection. The remaining registered trials include diagnostic tests, expanded access, epidemiological inquiry, health service research, basic science, prevention, meta-analysis, and studies of prognosis ( Figure 1b) . Although most trials were "Not applicable" without defined phases, there were 824 trials covering from Phases I~IV. Others include 117 retrospective studies and 6 new treatment trials for small sample pilot studies (Figure 1c ). From all listed trials, 1,067 were involved in pharmacologic interventions whereas 1,051 concerned other medical interventions, such as mechanical ventilation, continuous renal replacement therapy, mental status evaluation, diagnostic studies, and biomarker research. Of the pharmacological intervention trials, 873 were controlled and 194 lacked control arms. Controlled trials included 697 randomized and 176 non-randomized studies ( Figure 1d ).

The 1,067 medication intervention trials include 34 drugs, among which choloroquine and traditional Chinese medicine have the highest numbers of trials and patients (Table 1) . Chloroquine, a small molecule anti-malarial agent, showed efficacy in J o u r n a l P r e -p r o o f Journal Pre-proof inhibiting viral infection in cell assays (Wang et al., 2020a) . There are at least 180 clinical trials are underway, containing 215,842 participants. Traditional Chinese medicines, such as houttuynia mixture with qingfei prescription, honeysuckle decoction, Ba-Bao-Dan, Tanreqing capsules, and Shenqi Fuzheng are included in 121 trials enrolling 59,562 patients. Of the 1,067 medication intervention trials (Figure 1d ), 12 phase-III randomized placebo-controlled trials of 13,465 mild/moderate to severe COVID-19 patients are assessing the efficacy of remdesivir, a small molecule weight (MW=602.6) drug originally from Gilead Sciences (Foster City, California) that targets Ebola, Marburg, and MERS virus infections (Warren et al., 2016; Sheahan et al., 2020) . There are 19 trials with 18,130 patients testing the efficacy of lopinavir/ritonavir, protease inhibitors originally developed from the Abbott Laboratories (Lake Bluff, Illinois) to treat patients with human immunodeficiency virus (HIV) infections (Corbett et al., 2002) . Arbidol (also called Umifenovir) is another small molecule drug that has been mostly used in China and Russia to target influenza RNA virus (Haviernik et al., 2018) . A total of 10 trials and 3,177 patients are currently enrolled. Fourteen trials evaluate vaccine candidates in an aggregate of 10,325 participants. Some other major therapies include cytokine monoclonal antibody/inhibitors, convalescent plasma therapy, azithromycin and corticosteroids, as also listed in Table 1 .

The announced results from in vitro tests and clinical feedback from case studies and news reports suggest possible efficacy of at least 4 drugs, including remdesivir, chloroquine, lopinavir/ritonavir, and arbidol, although detailed clinical trial data are pending ( Figure 1 and Table 1 ). All these drugs have been reported previously to be effective in clinical use or in vitro tests against SARS-CoV or MERS-CoV (Agostini et al., 2018; Chu et al., 2004; Khamitov et al., 2008; Vincent et al., 2005) .

Remdesivir, a small molecule adenosine analogue, was proved effective at the stage of post SARS-CoV-2 entry (Wang et al., 2020a) . Chloroquine, a 70-year-old anti-malarial and autoimmune disease drug, can block virus infection in vitro at both the entry and post-entry stages of SARS-CoV-2 infection (Wang et al., 2020a) . These two drugs worked at low µM concentrations and showed high selectivity indices (SI) in Vero E6 cells infected with SARS-CoV-2 (Wang et al., 2020a) . Arbidol, a broad-spectrum antiinfluenza A/B drug, inhibited the activity of novel coronavirus at 10~30 µM concentrations from in vitro assays. Yet, many of these observations remain preliminary. Clinical reports have suggested a few drugs with possible efficacy for COVID-19 patients. A case report in the United States anecdotally indicated the effectiveness of remdesivir on a COVID-19 patient (Holshue et al., 2020) . A recent cohort of 53 patients hospitalized for severe COVID-19 from the United States, Canada, and Japan showed 68% improvement in oxygen saturation but with a mortality rate of 18% after 10 days of remdesivir (Grein et al., 2020) . Four patients with mild or severe COVID-19 pneumonia admitted to Shanghai Public Health Clinical Center showed significant improvement of symptoms after both the anti-viral treatment with lopinavir/ritonavir (Kaletra®), arbidol, and Shufeng Jiedu capsule (a traditional Chinese medicine) for 6~15 days together with antibiotics treatment and supplemental oxygen (Wang et al., 2020b ). Yet, a recent trial of 99 adults hospitalized with severe COVID-19 from China did not show significant

Once the SARS-CoV-2 reaches intracellular endosomes however, CatL becomes the major protease that cleaves the virus S1 subunit as this cysteinyl proteinase has an acidic pH optimum (Figure 3c ) (Chapman et al., 1997; Ou et al., 2020) . Indeed, SARS-CoV viruses have been considered pH-sensitive viruses and their intracellular trafficking requires an acidic environment (Chu et al., 2006) . While the serine protease TMPRSS2 acts locally at the host cell plasma membrane and possibly during endocytotic vesicle trafficking (Glowacka et al., 2011) , CatL continues S1 subunit degradation in the acidic endosome and lysosome compartments. This sequence of events explains the observations that the TMPRSS2 inhibitor camostat mesylate or a non-selective cysteinyl cathepsin inhibitor E64d could partially limit the SARS-CoV and SARS-CoV-2 infection of human epithelial cells. Combined use of both inhibitors fully blocked the infection of these coronaviruses (Hoffmann et al., 2020) . Although not tested in Hofmann's study, we hypothesize that combined use of TMPRSS2 inhibitor camostat mesylate and a CatL inhibitor will blunt substantially coronavirus infection of human cells.

Human cysteinyl cathepsins are the major proteases that reside in endosomes. This family composes 11 members that display acidic pH optima . Among this family of proteases, CatL cleaves the virus spike glycoprotein at the position of T678 (VAYT-M) (Bosch et al., 2008) , close to the predicted S1 and S2 boundary region of the SARS S protein (SARS-S) (Figure 3c ). After cleavage, the SARS-S S1 subunit is released from the S2 subunit. A fusion peptide on the S2 subunit inserts into the endosome membrane. Then the heptad repeats in the S2 subunit fold back and form a sixhelix-bundle structure (Simmons et al., 2013) . Subsequently, viral and endosome membranes coalesce and eventually fuse ( Figure 3d ). Coronaviridae then release their RNA into the cytoplasm of the host cells ( Figure 3e ). As a single-stranded, positive sense RNA virus, coronavirus has its own genetic material. The viral RNA can function as messenger RNA, directing the synthesis of viral proteins by host cell ribosomes without entering the nucleus ( Figure 2 ) (Positive stranded RNA virus replication. ViralZone. https://viralzone.expasy.org/1116). Therefore, CatL inhibition provides two sequential blocks for coronavirus infection: on the host cell surface to block virus entry and inside the host cell endosomes to block viral material release and replication. Before we discuss the potential advantage of CatL inhibition in maintaining human adaptive immunity, we will discuss the status of current CatL inhibitory drug development.

All seven CatL inhibitors have been tested on the infection of coronavirus pseudotypes and demonstrated inhibition of virus entry into host cells, although their pharmacology and toxicity varied. K11777 showed the lowest IC50 in SARS infection inhibition (Zhou et al., 2015) among all 7 listed inhibitors in Table 2 , although not all assays were performed in a single study. K11777, a vinyl sulfone cysteine protease inhibitor selected from screening of a library of proximately 2,100 cysteine protease inhibitors using the dual-envelop pseudotype (DEP) assay (Zhou et al., 2015) . It exhibited the inhibition of SARS-CoV infection at IC50 of 0.68 nM, with CC50>10 µM and MERS-CoV infection at IC50 of 46 nM through the cytopathic effect (CPE) inhibition assay. Three potent K11777 analogs, SMDC256122, SMDC256159 and SMDC256160 also showed strong anti-viral activity towards SARS-CoV pseudotypes with IC50 at 0.04 nM, 0.07 nM, and 0.08 nM, respectively. The anti-viral infection activity of K11777, SMDC256159, and SMDC256160 was validated on replication of competent SARS-CoV at IC50<0.05±0 nM, CC50>105.6±59.3 µM, SI>2112; IC50 0.65±0.81 nM, CC50>109.2±49.8 µM, SI>168; IC50 <0.08±0.05 nM, CC50=50.6±26.7 µM, SI>632.5, respectively. Furthermore, K11777 and its analogs have already proven safe in several parasitic infections in animals, compatible with the feasibility of K11777 for clinical uses (Doyle et al., 2007; Engel et al., 1998) .

The other six compounds possessed various potencies as virus infection inhibitor and for cytotoxicity. The most recently studied dec-RVKR-CMK showed inhibitory effects on MERS-CoV entry at noncytotoxic concentrations (2.5 to 100 µM) (Matsuyama et al., 2018) , with a decrease in the number of green fluorescent protein (GFP)-positive cells by 60% with VSV-∆G/GFP-MERS-S infection, tested in human epithelial cell lines LoVo cells and Calu-3 cells. A high-throughput library (Chembridge Diverset Library) screening using self-synthesized virus peptides identified a small molecule compound 5705213 (Elshabrawy et al., 2014) . It showed a relatively weaker capacity on SARS-CoV (IC50=9.0 µM) entry into the host 293FT cells compared with K11777. Although it showed dose-dependent inhibition of SARS-CoV entry and the CC50 was of 400 µM, leading to a low SI (CC 50 /IC 50 ) of 26.7. SSAA09E1, selected from the Maybridge Hitfinder chemical library using the SARS/HIV-luc pseudotyped virus infection assay, exerted inhibition on virus entry of ACE2-expressing 293T cells at EC50 of 6.7±0.4 µM, CC50>100 µM, SI>16 (Adedeji et al., 2013) . EST was reported as a cysteine protease inhibitor, including CatL. It showed strong inhibition on SARS-CoV entry when administered together with serine protease inhibitors, such as camostat mesylate (Kawase et al., 2012) . Oxocarbazate (PubChem CID 23631927) was initially designed based on the knowledge of the previously reported thiocarbazate chemotype (Shah et al., 2010; Myers et al., 2008) . It inhibited SARS-CoV infection at IC50 of 273±49 nM. In cultured human aortic endothelial cells, oxocarbazate did not display cytotoxicity at up to µM (Shah et al., 2010) . MDL28170, also known as calpain inhibitor-III or Z-Val-Phe-CHO, was first reported in 2005 (Simmons et al., 2005) . It inhibited the infection of SARS-CoV pseudovirus at IC95 of 2.0 µM.

Detailed CatL inhibition efficacy information is only available from three of the seven compounds listed in Table 2 . MDL28170 was selected from a library of pharmacologically active compounds. It showed potent CatL inhibition at IC50 of 2.5 nM (Simmons et al., 2005) . Oxocarbazate (PubChem CID 23631927), originally selected from a CatL assay in 2010, inhibits CatL activity at IC50 around 6.9 nM and acts as a slow-on, slow-off inhibitor (Shah et al., 2010) . SSAA09E1 was initially reported in 2013 to inhibit CatL activity with an IC50 of 5.33±0.61 µM (Adedeji et al., 2013) . Results showed that oxocarbazate had a similar inhibitory potency to MDL28170, but 1,000-fold more potent than SSAA09E1. Although no specific IC value was obtained from K11777, it was considered the most potent CatL inhibitor among the screened protease inhibitors (Zhou et al., 2015) . The other 3 compounds (dec-RVKR-CMK, EST, and 5705213) were also selected from validated CatL inhibitors, but their specific potencies remained incompletely reported.

The pharmacological details in Table 2 identify K11777 and oxocarbazate as the most attractive candidates for anti-coronavirus drugs. The available potency and safety assays identify CatL inhibitor K11777 as an efficacious drug candidate. Human pre-clinical trials are underway for K11777 as a potential treatment for patients with Chagas disease (Chaparro et al., 2018) , and the dose ranging and safety data from these trials may greatly shorten the preclinical and drug safety test time towards a novel therapeutic agent for COVID-19 patients. However, K11777 is an irreversible covalent inhibitor of CatL, and this irreversibility often entails unacceptable toxicity. In contrast, oxocarbazate is a reversible inhibitor of CatL and acts at a low concentration (Shah et al., 2010) , which meets the requirement for a potent, selective, and low toxicity candidate for human use. Detailed assays of oxocarbazate's activity against SARS-CoV-2 and relevant animal experiments should be conducted urgently.

Although several potential therapeutic CatL inhibitor candidates exist to date, such as K11777 and oxocarbazate, the ubiquitous expression of CatL raises concern for unwanted adverse effects of CatL inhibition. Therefore, we examined the inventory of the United States Food and Drug Administration (FDA)-approved drugs that may be effective in treating SARS-CoV-2 infections, and listed ten currently FDA-approved drugs that exhibit CatL inhibitiory activity in Table 3 , in which we sorted the list of drugs by type, including antimicrobial, antimalarial, immunomodulatory agents, and others. These already approved drugs may be redeployed to treat SARS-CoV-2 infection.

Several antimicrobial drugs inhibit CatL activity in human cells. Furthermore, these antimicrobial drugs can be classified as antibiotics (teicoplanin), anti-tuberculous drugs (rifampicin), anti-leprosy (clofazimine) and anti-HIV agents (saquinavir). Glycopeptide drugs such as teicoplanin can potently inhibit CatL activity in a dose-dependent manner (Zhou et al., 2016) . These drugs are usually used in the clinic to treat Gram-positive bacteria, especially Methicillin-resistant Staphylococcus aureus (S. aureus, MRSA) and S. pneumoniae, with low toxicity and relatively low safety concern. Bacterial superinfection commonly complicates viral pneumonitis, particularly in patients who require endotracheal intubation (Rice et al., 2012; Chertow and Memoli, 2013) . The J o u r n a l P r e -p r o o f teicoplanin family glycopeptide antibiotics merit particular consideration in this situation due to their anti-CatL activity. Notably, glycopeptide drugs such as teicoplanin can inhibit the infection of Ebola, MERS, SARS and SARS-CoV-2 viruses by inhibiting CatL Zhou et al., 2016) . A recent study from China published in bioRxiv suggested that teicoplanin can block SARS-CoV-2 infection in a dose-dependent manner in A549 cells, HEK293T cells, and huh7 cells . These encouraging findings support our hypothesis that targeting CatL can treat SARS-CoV-2 infection. Rifampicin and clofazimine inhibited CatL competitively or non-competitively, respectively (Kamboj et al., 2003) . Saquinavir prevented vascular damage by inhibiting CatL activity (Cai et al., 2017) .

The antimalarial drug, chloroquine can efectively block SARS-CoV-2 infection in cultured cells (Wang et al., 2020a) . This drug inhibits lysosomal cathepsins nonspecifically by increasing endosomal pH (Tang et al., 2018; Shivanna et al., 2014; Wang et al., 2020a) . Chloroquine also affects the CDP/Cux transcription factor at neutral pH, indicating that it can directly affect protease synthesis (Goulet et al., 2004) . Although chloroquine could have short-term benefit to COVID-19 patients by inhibiting CatL activity, it remains unproven, and can predispose to cardiac arrhythmia (Tonnesmann et al., 2013) . Non-selective inhibition of endosomal proteases, including cathepsins may cause unwanted effects in patients, as we will discuss further.

Some immunomodulatory drugs have a proven role in inhibiting CatL. Dexamethasone inhibits CatL in muscle cells. Astaxanthin, a potential immunomodulatory antioxidant agent, can suppress CatL activity in both Syrian hamster embryo cells and muscle cells (Shibaguchi et al., 2016) . Many individuals with advanced SARS-CoV-2 infection have cytokine storm, often a harbinger of fatal outcome. This uncontrolled elevation of cytokines can lead to disseminated intravascular coagulation and multiple organ system failures (Chertow and Memoli, 2013; Rice et al., 2012) . In survivors, the long-term consequences of cytokine storm may lead to pulmonary fibrosis, causing functional disability and reduction in quality of life (Chertow and Memoli, 2013; Rice et al., 2012) . Interrupting of this exaggerated inflammatory response should be a priority. To this end, trials discussed in Table 1 are evaluating anti-cytokine therapy, glucocorticoids, and interferon- treatment for COVID-19-infected patients with adult respiratory distress syndrome (ARDS) and cytokine storm.

Clenbuterol and heparin weakly inhibit CatL and may have adjunctive value in the certain situations in COVID-19 disease. Pneumonia can induce bronchospasm (Goncalves et al., 2012; Higgins et al., 2010) . Clenbuterol, an inhaled selective 2adrenergic agonist can limit CatL mRNA levels (Goncalves et al., 2012) . COVID-19 patients have a high risk of deep vein thrombosis and those in need of anticoagulant therapy, heparin merits consideration as it may accelerate CatL inhibition by serpins (Higgins et al., 2010) . Although not US FDA-approved, some Chinese medicine extracts can also inhibit CatL activity and broadly used among patients. MOL736, also called J o u r n a l P r e -p r o o f Journal Pre-proof aurantiamide acetate that inhibits CatL activity, may relieve cough and reduce sputum production (Wang et al., 2007) . The water and ethanol extracts of drynariae rhizoma also showed significant CatL inhibitory activities . Numerous clinical trials underway will evaluate the therapeutic efficacy of these traditional Chinese medicines on COVID-19 (Table 1) . Those preparations that exhibit CatL inhibitory properties may have particular potential as drug candidates for COVID-19.

Development and validation of a therapy for COVID-19 presents a major and imminent challenge to society and medicine. Although several drugs show efficacy in inhibiting SARS-CoV-2 replication or infectious activity in vitro, clinical trials will require many months. Compassionate use of remdesivir in the first confirmed case in the United States and a recent study of 53 patients showed possible efficacy (Grein et al., 2020; Holshue et al., 2020) , but the clinical effectiveness and safety of such agents requires validation in rigorous controlled clinical trials.

In 2013, Bertram et al. proved that CatL-selective inhibitor MDL-28170 (Table 2) completely blocked the entry of HCoV-229E when the same dose (10 µM) of MDL-28170 was used together with 1 µM of TMPRSS2 inhibitor camostat mesylate, equivalent or significantly more potent than the inhibitory activity from 100 µM camostat mesylate alone depending on the host cell types (Bertram et al., 2013) , suggesting a synergic role of CatL and TMPRSS2 in cellular penetration of coronavirus HCoV-229E (Figure 3a ). A recent report tested the efficacy of TMPRSS2 inhibitor camostat mesylate in SARS-CoV and SARS-CoV-2 infection (Hoffman et al., 2020) . Camostat mesylate reduced the entry of these viruses into host cells that express TMPRSS2, and the pancathepsin inhibitor E64d blocked virus entry independent of TMPRSS2 expression. Again, combined use of E64d and camostat mesylate showed complete inhibition of SARS-CoV and SARS-CoV-2 entry into either TMPRSS2-positive or negative host cells (Hoffman et al., 2020) . Although none of these studies used camostat mesylate combined with a CatL inhibitor in studying specifically SARS-CoV-2 infection, these prior findings provide encouragement with regard to COVID-19 treatment. First, camostat mesylate has been successfully and safely used to treat patients with chronic pancreatitis in Japan, and a randomized controlled trial has recently been completed in the Unites States (Ramsey et al., 2019) . Use of these market drugs will help offset our potential side effect or toxicity concerns. Second, SARS-CoV-2 infection not only infects the respiratory tract, but also affects other organs in which not all cells express TMPRSS2 (Hoffman et al., 2020; Sungnak, et al., 2020) . A protease inhibitor cocktail approach using camostat mesylate together with a CatL inhibitor listed in Table 2 or even a FDA-approved CatL inhibitory drug listed in Table 3 might offer clinical improvement for COVID-19 patients by not only preventing lung epithelial cell infection, but also reducing the risks of SARS-CoV-2-induced damage in other cell types and organs with even much lower doses for each inhibitor than using camostat mesylate or CatL inhibitor alone.

While the combined use of TMPRSS2 inhibitor camostat mesylate and hydroxychloroquine has been included in two clinical trials (NCT04355052, J o u r n a l P r e -p r o o f NCT04338906), CatL inhibition should merit immediate consideration. Here we discuss the advantages of CatL inhibitor and camostat mesylate dual therapy versus of camostat mesylate or CatL inhibitor monotherapy, and potential concerns of chloroquine treatment. The known molecular and cellular mechanisms of each of these drugs will help interpret the observations for the upcoming clinical data from the 4 on-going camostat mesylate trials (NCT04355052, NCT04338906, NCT04353284, NCT04321096) and 180 on-going chloroquine trials (Table 1 ) and underscore the rationale of our proposed TMPRSS2 and CatL inhibitor cocktail therapy.

We propose three beneficial functions of CatL inhibition in SARS-CoV-2 infections: blocking the virus entry on the host cell surface together with TMPRSS2 serine protease inhibition (e.g. camostat mesylate) (Figure 3a) , blocking virus membrane fusion in the endosome essential for release of the virion's genetic material and replication (Figure 3c -3e), while not interfering with other essential protease activities of normal immune responses such as T-cell activation and anti-viral antibody production. When endosomal CatL activity in thymocytes and splenocytes is required for CD4 + positive selection (Nakagawa et al., 1998; Honey et al. 2002) , cathepsin S (CatS) is the major endosomal protease responsible for peripheral immune responses and antibody production (Riese et al., 1996; Shi et al., 1999; Beers et al., 2005) . The proposed dual protease inhibitor therapy could combat SARS-CoV-2 infections not only at the entry point on the plasma membrane of the host cells, but also in the endosome, serial steps in viral pathogenesis in addition to preserving adaptive immunity.

Recent rudimentary clinical evidence suggested the efficacy of antimalarial chloroquine and its analogs hydroxychloroquine and chloroquine phosphate in COVID-19 patients. To date no registered clinical trial has supported this conjecture. Chloroquine affects ACE2 terminal glycosylation (Vincent et al., 2005) which affects by turn coronavirus host cell attachment. This mechanism could contribute to the reported efficacy of chloroquine (hydroxychloroquine or chloroquine phosphate) in COVID-19 patients (Fox, 1993; Yao et al., 2020) . A further mechanism of chloroquine relative to the CatL function discussed here is its activity in raising endosomal pH (Al-Bari, 2017), thereby non-selectively inactivating all endosomal proteases including CatL whose optimal activity requires an acidic environment. By raising the endosomal pH, chloroquine blocks the proteolysis of virus surface spike protein S1 subunit in the endosomes and reduces the viral genetic material release. However, increased endosomal pH could interfere with all endosomal proteases, including CatS and CatL, which process and present viral antigens to activate T cells and to enhance antibody production ( Figure  4 , left side). It is presently unknown whether COVID-19 patients showed altered cytotoxic T-cell activity or anti-viral antibody titers after chloroquine treatment versus other therapies. We hypothesize here that chloroquine and congeners could impair adaptive immune responses. Although detailed mechanisms remain unknown, numerous cases of COVID-19 patients have become viral positive and relapsed after hospital discharge . This scenario could result from defective adaptive immunity. In this regard, CatL inhibitors, or the proposed protease inhibitor cocktail therapy, could J o u r n a l P r e -p r o o f have advantages over chloroquine. Patients or cells treated with CatL specific inhibitors, with or without camostat mesylate, unlike those treated with chloroquine, should not display a reduction in the favorable activity of the other endosomal proteases. These proteases, including CatS (Beers et al., 2005) , degrade viral proteins, generate antigenic viral peptides, and assist MHC class-1 and MHC class-II antigenic peptide loading and presentation in the endosomes (Figure 4, right side) . Therefore, host cell MHC-I-and MHC-II-mediated antigen presentation and CD8 + and CD4 + T-cell activations would remain unaffected. Earlier studies showed that CatL or CatS can mediate invariant chain proteolysis and antigen presentation in thymic and intestinal epithelial cells, while CatS cleaves invariant chain involved in antigen presentation by professional antigen presenting cells (APCs) (Beers et al., 2005; Nakagawa et al., 1998; Shi et al., 1999) . Likewise, bronchial and alveolar type-2 epithelial cells constitutively express MHC class-I and MHC class-II molecules (Corbiera et al., 2011; Gereke et al., 2009; Wosen et al., 2018) . Maintenance of endosomal protease activity in lung epithelial cells to maintain or enhance cytotoxic T-cell activity and antibody production may prove salutary during and after coronavirus infection. In contrast, chloroquine and its derivatives will raise the endosomal pH and inactivate all endosomal proteases, including CatL and CatS. Chloroquine's potential for limiting coronavirus infection might come at the cost of impairing the adaptive immune responses, a mechanism by which these drugs may benefit autoimmune diseases such as lupus erythematosus (Figueroa-Parra et al., 2019) . Although lung epithelial cells are not the major cell type responsible for T-cell activation and antibody production, chloroquine and congeners could mute the antigen processing and presentation functions in the endosome (Figure 4 , left side).

Professional APCs, such as B cells and dendritic cells, initiate specific cytotoxic Tcell activation and antibody production. Prior studies showed that coronavirus infection reduces the expression of MHC class-I and MHC class-II molecules and associated molecules (Menachery et al., 2018; Josset et al., 2013) thereby reducing anti-viral cytotoxic CD8 + T-cell (Liu et al., 2010) and CD4 + T-cell activation (Yang et al., 2009) . Chloroquine-mediated endosomal pH increase will result in APC loss-of-function because of endosomal protease inactivation ( Figure 5, left) . In contrast, CatL inhibitors (e.g. teicoplanin and oxocarbazate) will not affect the activities of CatS and other endosomal proteases necessary for viral antigen processing and presentation in APCs. Therefore, these agents, unlike chloroquine, will not affect the APC functions in CD4 + and CD8 + T-cell activation and anti-viral antibody production ( Figure 5, right) . Figures 4 and 5 , CatL inhibition, either with its selective inhibitor or in a protease cocktail with the serine protease inhibitor camostat mesylate proposed in this manuscript, might protect COVID-19 patients from coronavirus infection without affecting the adaptive immunity. This beneficial function of CatL inhibition is implicated in three significant ways. First, CatL inhibition blocks coronavirus surface spike protein S1 subunit cleavage on host cell surface, as a mechanism to block coronavirus initial infection. Second, CatL inhibition blocks virus membrane fusion in host cell endosomes, as a mechanism to block coronavirus replication. Third, CatL-selective inhibition leaves other endosome proteases active for coronavirus protein processing and antigen J o u r n a l P r e -p r o o f presentation in epithelial cells, APCs, and other non-professional APCs for T-cell activation and anti-viral antibody production.

The worldwide and severe COVID-19 pandemic calls for treatments before and even after vaccines become available. This article highlights the importance of CatL in coronavirus infection, particularly SARS-CoV-2, and proposes a hypothesis for treament of COVID-19 by targeting CatL activity. This publication also aims to bring to light existing CatL inhibitor compounds, particularly FDA-approved drugs, that may potentiate treatments for the current COVID-19 pandemic. These FDA-approved CatL inhibitory drugs provide a COVID-19 antiviral therapy that may be appropriate for patients depending on their current medical conditions, especially for those newly exposed to the virus or who test positive for the virus but are asymptomatic, when the early infection may be more clinically manageable. Therapeutic applications of CatL inhibitors, including some currently FDA-approved, employed alone or more preferably together with the serine protease inhibitor camostat mesylate, may emerge from both basic and clinical studies to as proving value in COVID-19 treatment. As camostat mesylate has broad use among chronic pancreatitis patients, and a number of drugs that can inhibit CatL already have FDA approvals, we advocate testing of this protease inhibitor cocktail approach for management of COVID-19 patients. We also point out how chloroquine and analogs may impair the human adaptive immune system ability to fight virus infection. In contrast, the proposed protease inhibitor cocktail approach may both inhibit virus infection and activate adaptive immunity. We advocate testing the combined inhibition of CatL and the serine protease TMPRSS2 as a novel treatment for COVID-19 patients.

In the absence of clinical trials for our proposed dual protease inhibitor therapy, we can merely speculate regarding its efficacy in COVID-19 patients and cannot predict possible adverse effects of this approach. As discussed, CatL inhibition may impair CD4 + T-cell thymic selection (Nakagawa et al., 1998; Honey et al. 2002) . We recently showed that chronic use of cathepsin inhibitors may associate with tissue fibrosis Fang et al., 2020) . Pulmonary fibrosis during the healing of acute lung injury due to COVID19 infection could be a concern. These possible adverse effects may be avoided as CatS is the major endosomal proteases that mediates antigen presentation and antibody production (Shi et al., 1999; Beers et al., 2005 ) and short-term use of CatL inhibitors for acute coronavirus infection should not affect tissue fibrosis appreciably.

Camostat mesylate from bio-japan.net is relatively inexpensive (100 -100 mg tablets list at $39.90). Six pills a day for chronic pancreatitis treatment costs about $2.00. For patients with organ infections, a maximum of 600~1000 mg teicoplanin per day intramuscular administration (Rybak, 1993) is recommended, depending on creatinine clearance. Targocid from Sanofi Aventis is currently not used in the United States, but widely in Europe, Asia, and South America. It costs about $22.00 each 400 mg for injection or oral dose based on ndrugs.com, or $44.00 per day. This article proposes urgent consideration of collaborators, physicians, COVID-19 patients, and medical centers to explore this promising possibility to fight for COVID-19 and possible mutants J o u r n a l P r e -p r o o f that may develop.

TgCPB and TgCPL, are targeted by the vinyl sulfone inhibitor K11777 in in vitro and in vivo models of toxoplasmosis. PLoS One, 13, e0193982. Chapman, H.A., Riese, R.J., & Shi, G.P. (1997) . Emerging roles for cysteine proteases in human biology. Annu Rev Physiol, 59, 63-88. Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., Xia, J. a., Yu, T., . Most are intervention studies and observation studies. The remaining includes diagnostic test (image diagnosis, IgG and IgM test, nucleic acid or RNA test compared with the golden standard test); expanded access, sometimes called "compassionate use" (a potential pathway for a patient with an immediate life-threatening condition or serious disease or condition to gain access to an investigational medical product -drugs, biologics, or medical devices-for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available); epidemiological research (mainly cross-sectional studies discribing the clinical features of COVID-19, psychological status, or biomarkers); basic science (trials with detailed basic cellular and molecular studies of patients); health services reaserch (evaluation of health service providers' mental status or pretection measures); prevention study (evaluates the effectiveness of the medication or preventive protocoles); Meta-analysis (statistical procedure for combining data from multiple studies); prognosis study (analyzes the clinical outcomes from study cohorts); and screening study (studies of patient CT scan reaults). c. Clinical trials sorted by different phases. Not applicable trials include those without phase information. Retrospective study includes mainly the case controls or case series studies based on dataset from medical record. New treatment includes studies for small sample pilot studies (such as rehabilitation, plasma therapy, or traditional Chinese medicine) that are mainly from ChiCTR. d. Clinical trials grouped by non-medication intervention and medication intervention that is further grouped as uncontrolled and controlled trials. Controlled trials include randomized and non-randomized trials.

Diagram of the lung type-II alveolar epithelial cell (ATII) SARS-CoV-2 infection pathway. This pathway includes initial SARS-CoV-2 surface spike protein J o u r n a l P r e -p r o o f proteolysis by ATII cell surface TMPRSS2 and CatL and then binding of SARS-CoV-2 to ATII cell surface receptor ACE2, followed by endocytosis. Membrane fusion occurs between the virus containing vesicles and endosome, resulting virus delivery into the endosomes where CatL cleaves the S1 subunits. The remaining S2 subunit on virus surface mediates virus fusion with the endosome membrane, leading to virus ssRNA exocytosis into the cytosol, where the virus replicates and directs protein synthesis (via host ribosomes), and the progeny virions assemble, acquire their coat, and exit the host cell to propagate infection to healthy cells. Figure 3 . Possible mechanism of CatL activity in mediating SARS-CoV-2 infection and replication. a. SARS-CoV-2 binding between the S protein S1 subunits and the cell surface ACE2 receptor. b. Plasma membrane endocytosis together with the SARS-CoV-2. In these newly formed vesicles, SARS-CoV-2 remains attached with the ACE2 receptor. c. SARS-CoV-2 targets to the endosomes where CatL cleaves the S1 subunits and frees the virus. d. Virus membrane fusion with the endosome membrane, leaving a gap at the fusion site. e. Endosome releases virus ssRNA into the cytosol where virus RNA produces viral proteins and packages new virus particle to release for next round of infections. Figure 4 . Advantage of protease inhibitor cocktail therapy over chloroquine in the treatment of patients with coronavirus infection -Epithelial cells. Both serine protease TMRPSS2 and CatL appear to be involved on the epithelial cell plasma membrane S1 subunit cleavage to assist coronavirus endocytosis. Chloroquine and its analogs raise endosome pH and non-selectively inactivate all endosomal proteases including CatL and CatS, thereby blocking S1 subunit proteolysis and CatL and CatS activities in antigen presentation (left side). In contrast, CatL-specific inhibition (e.g. teicoplanin and oxocarbazate) selectively blocks S1 subunit proteolysis, leaving other endosomal proteases active for their essential roles in antigen processing and presentation. Remaining endosome proteases, including CatS, generate antigenic peptides and assist MHC-I-and MHC-II-mediated antigen presentation and CD8 + and CD4 + T-cell activation (right side). 

Alveolar type II epithelial cells present antigen to CD4(+) T cells and induce Foxp3(+) regulatory T cells

Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response

Secondary household transmission of SARS

Clenbuterol suppresses proteasomal and lysosomal proteolysis and atrophy-related genes in denervated rat soleus muscles independently of Akt

A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor

Arbidol (Umifenovir): A Broad-Spectrum Antiviral Drug That Inhibits Medically Important Arthropod-Borne Flaviviruses. Viruses

Heparin enhances serpin inhibition of the cysteine protease cathepsin L

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

First Case of 2019 Novel Coronavirus in the United States

The endosomal-lysosomal system: from acidification and cargo sorting to neurodegeneration

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet

Inhibitory activity of Drynariae rhizoma extracts on cathepsin having bone resorption activity

Promotive Association for

Inhibitory activity of Drynariae rhizoma extracts on cathepsin having bone resorption activity

Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus

Effects of some antituberculous and anti-leprotic drugs on cathepsins B, H and L

Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry

Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures

Structure, Function, and Evolution of Coronavirus Spike Proteins

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

Cathepsin B and L inhibitors: a patent review (2010 -present)

Cysteine protease cathepsins in cardiovascular disease: from basic research to clinical trials

Novel immunodominant peptide presentation strategy: a featured HLA-A*2402-restricted cytotoxic T-lymphocyte epitope stabilized by intrachain hydrogen bonds from severe acute respiratory syndrome coronavirus nucleocapsid protein

Secondary attack rate and superspreading events for SARS-CoV-2. The Lancet

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Middle East Respiratory Syndrome Coronavirus Spike Protein Is Not Activated Directly by Cellular Furin during Viral Entry into Target Cells

MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering the epigenetic landscape

Identification of the first synthetic inhibitors of the type II transmembrane serine protease TMPRSS2 suitable for inhibition of influenza virus activation

Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein

Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV

Identification and synthesis of a unique thiocarbazate cathepsin L inhibitor

Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus

Modulatory effect of dexamethasone on ornithine decarboxylase activity and gene expression: a possible post-transcriptional regulation by a neutral metalloprotease

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Simulating henipavirus multicycle replication in a screening assay leads to identification of a promising candidate for therapy

A phase 1/2 trial to evaluate the pharmacokinetics, safety, and efficacy of NI-03 in patients with chronic pancreatitis: study protocol for a randomized controlled trial on the assessment of camostat treatment in chronic pancreatitis (TACTIC)

Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States

Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading

Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany

Teicoplanin vs vancomycin: cost-effectiveness comparisons

A smallmolecule oxocarbazate inhibitor of human cathepsin L blocks severe acute respiratory syndrome and ebola pseudotype virus infection into human embryonic kidney 293T cells

The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Cathepsin S required for normal MHC class J o u r n a l P r e -p r o o f II peptide loading and germinal center development

COVID-19 infection: the perspectives on immune responses

Astaxanthin intake attenuates muscle atrophy caused by immobilization in rats

Endosomal acidification and cathepsin L activity is required for calicivirus replication

Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry

Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research

Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2

SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes

Hydroxychloroquine attenuates renal ischemia/reperfusion injury by inhibiting cathepsin mediated NLRP3 inflammasome activation

Chloroquine cardiomyopathy -a review of the literature

Transmissibility of MERS-CoV Infection in Closed Setting

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Endocytosis of the receptor-binding domain of SARS-CoV spike protein together with virus receptor ACE2

Virtual screening for finding natural inhibitor against cathepsin-L for SARS therapy

Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia and Western medicine treatment

Epithelial MHC Class II Expression and Its Role in Antigen Presentation in the Gastrointestinal and Respiratory Tracts

Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2

Searching immunodominant epitopes prior to epidemic: HLA class II-restricted SARS-CoV spike protein epitopes in unexposed individuals

Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus

Teicoplanin potently blocks the cell entry of 2019-nCoV

Differential Roles of Cysteinyl Cathepsins in TGFbeta Signaling and Tissue Fibrosis. iScience

Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)

Protease inhibitors targeting coronavirus and filovirus entry

A Novel Coronavirus from Patients with Pneumonia in China

Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection

Reducing mortality from 2019-nCoV: host-directed therapies should be an option

*Drug list is sorted based on study patient size. **Notes: Chloroquine: hydroxychloroquine, chloroquine phosphate

Cytokine m Ab/inhibitor: IL6 monoclonal antibodies tocilizumab, siltuximab, sarilumab, and clazakizumab; complement component 5 inhibitors ravulizumab and eculizumab; PD-1 blocking antibody nivolumab

human granulocyte macrophage colony-stimulating factor receptor inhibitors mavrilimumab and gimsilumab; IL17A antagonist ixekizumab, IL1 antibody canakinumab; vascular endothelial-derived growth factor antibody bevacizumab; IL1 receptor antagonist anakinra; anti-C5a receptor antibody avdoralimab

Anticoagulants: lowmolecular-w eight heparin, recombinant tissue-plasminogen activator, and nebulized heparin sodium; Interferons: IFN-1b Eye Drops, IFN-1b, IFN-1a, IFN atomization, IFN-1b spray, recombinant super-compound IFN; IFN aerosol inhalation; Anti-microbial/antibiotics: doxycycline, carrimycin, povidone-iodine, and levamisole; Diuretics: thiazide and spironolactone; Stem cells therapies: stem cells therapy, mesenchymal stem cells, adult allogeneic bone marrowderived mesenchymal stromal cells, allogenic adipose tissue-derived mesenchymal stem cells, dental pulp mesenchymal stem cells

Antiviral m edications: oseltamivir and baloxavir marboxil

IgG products manufactured from pooled human plasma and typically contain more than 95% unmodified IgG) and immunoglobulin from cured patients; Im m une cell therapy: NK cells; mononuclear cells; umbilical cord blood cytokine-induced killer cells; HIV protease inhibitors: ritonavir and darunavir/cobicistat; Others: oral nutrition supplements, nonsteroidal anti-inflammatory drugs, antihypertension drugs

The authors thank Robert B. Gregory of Damariscotta, Maine for providing editorial assistance in the preparation of this review. This work was supported by grants from the National Institute of Health (HL080472 and HL134892 to PL, and HL123568, HL60942, and AG063839 to GPS).

 Table 1 . List of drugs from on-going clinical trials for COVID-19 patients (up to May 12, 2020 J o u r n a l P r e -p r o o f